TY  - JOUR
AU  - Paz Ares, Luis Gonzaga
AU  - Barlesi, F
AU  - Siena, S
AU  - Ahn, M-J
AU  - Drilon, A
AU  - Conley, A
AU  - Rolfo, C
AU  - Wolf, J
AU  - Seto, T
AU  - Doebele, R
AU  - Kapre, A
AU  - Chen, D
AU  - McCallum, S
AU  - Osborne, S
AU  - Demetri, G
PY  - 2021
DO  - 10.1016/j.esmoop.2021.100113
UR  - http://hdl.handle.net/20.500.12105/13323
AB  - Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk-benefit profiles, in addition to efficacy and safety data. We investigated the impact of entrectinib on patient-reported...
LA  - eng
PB  - Elsevier
KW  - Tyrosine kinase inhibitor
KW  - ROS1
KW  - Patient-reported outcomes
KW  - NTRK
KW  - Entrectinib
TI  - Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
TY  - journal article
ER  -